Amgen's Kyprolis wins FDA myeloma nod; AZ sells thyroid drug to Sanofi's Genzyme;

> The FDA has approved Kyprolis for combo use in the treatment of patients with relapsed multiple myeloma. Release

> Bristol-Myers Squibb's ($BMY) hep C pill, Daklinza, has won FDA approval to be used in combination with Gilead's ($GILD) Sovaldi. Release

> AstraZeneca ($AZN) has inked a $300 million pact to sell thyroid carcinoma drug Caprelsa to Sanofi's ($SNY) Genzyme. Story

> After the close of Teva's ($TEVA) $40.5 billion deal for Allergan's generics business, the Israeli drugmaker will boast a commercial presence in 100 markets, including a top-three position in more than 40 of those markets, it said Monday. Release

And Finally... Television's Dr. Oz made $1.17 million off a hemorrhoid treatment he promoted in his column, Vox reports. More

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.